Corient IA LLC Takes $1.51 Million Position in Intuitive Surgical, Inc. $ISRG

Key Points

• Corient IA LLC has acquired 3,050 shares of Intuitive Surgical, valued at approximately $1,511,000, making it the 6th largest holding in their portfolio.
• Institutional investors, including Vanguard and Invesco, continue to increase their holdings in Intuitive Surgical, suggesting strong institutional interest as 83.64% of the stock is owned by such entities.
• Recent price targets for Intuitive Surgical from various analysts range from $440 to $684, reflecting differing views on the company's future performance in the market.

Corient IA LLC acquired a new position in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 3,050 shares of the medical equipment provider's stock, valued at approximately $1,511,000. Intuitive Surgical comprises about 1.1% of Corient IA LLC's investment portfolio, making the stock its 6th biggest position.

Several other institutional investors also recently modified their holdings of ISRG. Chilton Capital Management LLC grew its stake in shares of Intuitive Surgical by 614.3% in the first quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 43 shares during the last quarter. Parvin Asset Management LLC bought a new stake in Intuitive Surgical during the fourth quarter valued at $26,000. Global Financial Private Client LLC boosted its position in Intuitive Surgical by 253.3% during the first quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock valued at $26,000 after acquiring an additional 38 shares during the last quarter. Elite Financial Inc. bought a new stake in Intuitive Surgical during the first quarter valued at $26,000. Finally, LFA Lugano Financial Advisors SA bought a new stake in Intuitive Surgical during the first quarter valued at $30,000. Institutional investors own 83.64% of the company's stock.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, insider Gary S. Guthart sold 2,800 shares of the stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $495.24, for a total value of $1,386,672.00. Following the completion of the sale, the insider owned 18,520 shares in the company, valued at approximately $9,171,844.80. This trade represents a 13.13% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Myriam Curet sold 4,500 shares of the stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $492.48, for a total transaction of $2,216,160.00. Following the completion of the sale, the executive vice president owned 353 shares of the company's stock, valued at approximately $173,845.44. This trade represents a 92.73% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 15,839 shares of company stock worth $7,896,972. Insiders own 0.70% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have commented on ISRG shares. Piper Sandler reaffirmed an "overweight" rating and set a $595.00 price target (up previously from $575.00) on shares of Intuitive Surgical in a research report on Wednesday, July 23rd. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $615.00 price target on shares of Intuitive Surgical in a research report on Tuesday. BTIG Research upped their price target on shares of Intuitive Surgical from $566.00 to $571.00 and gave the company a "buy" rating in a research report on Wednesday, July 23rd. Truist Financial upped their price target on shares of Intuitive Surgical from $590.00 to $600.00 and gave the company a "buy" rating in a research report on Wednesday, July 23rd. Finally, Citigroup reiterated a "buy" rating and set a $650.00 price objective (up previously from $590.00) on shares of Intuitive Surgical in a report on Thursday, May 22nd. Thirteen investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Intuitive Surgical currently has a consensus rating of "Moderate Buy" and an average price target of $595.95.

Intuitive Surgical Trading Up 0.3%

Shares of ISRG traded up $1.25 on Wednesday, reaching $480.45. The company's stock had a trading volume of 1,409,146 shares, compared to its average volume of 1,989,028. Intuitive Surgical, Inc. has a twelve month low of $425.00 and a twelve month high of $616.00. The stock has a market capitalization of $172.23 billion, a PE ratio of 67.01, a PEG ratio of 5.04 and a beta of 1.59. The firm has a fifty day moving average of $506.84 and a 200-day moving average of $523.82.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share for the quarter, topping analysts' consensus estimates of $1.93 by $0.26. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. The company had revenue of $2.44 billion for the quarter, compared to analyst estimates of $2.35 billion. During the same quarter in the prior year, the business posted $1.78 EPS. The firm's revenue was up 21.4% compared to the same quarter last year. As a group, equities analysts anticipate that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.